托吡酯对利培酮所致体质量变化及血浆瘦素的影响

Effect of treatment with topiramate on risperidone-induced weight mass variation and plasma leptin levels

目的探讨精神分裂症患者使用托吡酯干预对利培酮所致体质量变化的影响。方法将76例首发精神分裂症患者随机分为研究组(38例)和对照组(38例),研究组应用利培酮联合托吡酯治疗,对照组单用利培酮治疗,为期6周。比较治疗前后两组患者体质量和血浆瘦素水平变化。结果研究组患者治疗后体质量与治疗前比较([56.9±10.6)kg vs(.56.2±10.7)kg],差异无统计学意义(P>0.05),对照组治疗后体质量较治疗前增加([57.6±10.2)kg vs(.55.8±11.4)kg],差异有统计学意义(P<0.01);研究组([8.8±2.0)μg/L vs(.7.2±2.4)μg/L]和对照组([8.2±1.8)μg/L vs(.6.8±2.7)μg/L]治疗后血浆瘦素水平较治疗前均升高,差异均有统计学意义(P<0.01)。结论托吡酯干预能有效阻止利培酮所致体质量增加,对血浆瘦素水平的影响不大。

Objective To explore the effect of topiramate on risperidone-induced weight mass variation. Method Seventy-six first-episode schizophrenics were randomly divided into study group and control group. Study group received combination of topiramate and risperidone treatment whereas control group received risperidone treatment only. The variation of body mass and plasma leptin levels were measured before and 6 weeks after treatment. Results There was no significant difference in the body mass between before and six weeks after treatment in study group [ （ 56.9± 10.6 ） kg vs. （ 56.2± 10.7 ） kg,（P〈0.05）]. The body mass significantly increased after the treatment in control group [（57.6± 10.2） kg vs. （55.8±11.4） kg, （P〈0.01）]. The plasma leptin levels significantly increased in both groups after treatment （P〈0.01）. Conclusions Topiramate can effectively prevent risperidone-induced weight mass gain whereas has no influence on plasma leptin levels.